ClinicaliQ Trial Snapshot
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting • Phase III • Oncology • NCT05899608.
- Treatment Being Tested: Ivonescimab (a dual TIGIT/PD-L1 pathway inhibitor) combined with chemotherapy compared to pembrolizumab (PD-L1 inhibitor) combined with chemotherapy as first-line therapy for metastatic NSCLC, with primary endpoints of overall survival and progression-free survival.
- Patient Eligibility: Adults with previously untreated metastatic non-small cell lung cancer suitable for first-line chemotherapy; the study is multiregional and randomised in a double-blind design, suggesting inclusion of diverse patient populations across different geographical settings.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Eligibility Snapshot
- : * Age ≥ 18 years old at the time of enrollment * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Expected life expectancy ≥ 3 months * Metastatic (Stage IV) NSCLC * Histologically or cytologically confirmed squamous or non-squamous NSCLC * Recorded measurement of the Tumor Proportion Score (TPS) or Tumor Cells (TC) for PD-L1 expression, irrespective of the PD-L1 expression, prior to randomization * At least one measurable noncerebral lesion according to RECIST 1.1 * No prior systemic treatment for metastatic NSCLC
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.